NCT06814717View on ClinicalTrials.gov

A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 5% Total Body Surface Area Burns

PHASE2RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

November 1, 2026

Conditions
Thermal Burns
Interventions
DRUG

cP12

cP12 is a novel fibronectin derived, 14-mer peptide

Trial Locations (1)

20010

RECRUITING

Medstar Washington Hospital Center, Washington D.C.

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Neomatrix Therapeutics, Inc.

OTHER

NCT06814717 - A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 5% Total Body Surface Area Burns | Biotech Hunter | Biotech Hunter